KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBT (2016 - 2025)

Pacific Biosciences Of California has reported EBT over the past 16 years, most recently at -$40.2 million for Q4 2025.

  • Quarterly results put EBT at -$40.2 million for Q4 2025, down 1594.94% from a year ago — trailing twelve months through Dec 2025 was -$546.1 million (down 76.41% YoY), and the annual figure for FY2025 was -$546.1 million, down 76.41%.
  • EBT for Q4 2025 was -$40.2 million at Pacific Biosciences Of California, down from -$37.6 million in the prior quarter.
  • Over the last five years, EBT for PACB hit a ceiling of $2.7 million in Q4 2024 and a floor of -$426.4 million in Q1 2025.
  • Median EBT over the past 5 years was -$71.4 million (2022), compared with a mean of -$85.9 million.
  • Biggest five-year swings in EBT: surged 103.25% in 2024 and later crashed 1594.94% in 2025.
  • Pacific Biosciences Of California's EBT stood at -$68.2 million in 2021, then fell by 23.81% to -$84.4 million in 2022, then increased by 1.95% to -$82.7 million in 2023, then surged by 103.25% to $2.7 million in 2024, then plummeted by 1594.94% to -$40.2 million in 2025.
  • The last three reported values for EBT were -$40.2 million (Q4 2025), -$37.6 million (Q3 2025), and -$41.9 million (Q2 2025) per Business Quant data.